Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)

The requested reference [af295c2675d6baf7beac5b30cda6e16409e9fd30] no longer exists in our database. It has been replaced by the current reference: [e975b2d9a233dc0bef82e9747e3311f455d17389]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
The aim of this study is to evaluate the involvement of small airways in asthma, as determined by bronchial challenges, CT-scanning, and cellular markers of inflammation. Ciclesonide will be inhaled at one dose level once daily. The study duration consists of a baseline period (2 to 3 weeks) and a treatment period (5 to 6 weeks). The study will provide further data on safety and tolerability of ciclesonide.
Epistemonikos ID: a8230658c81768755dfe198d6ccc875a457cca0f
First added on: May 04, 2024